Risk-based diagnostic pathways that combine equivocal prostate MRI findings with prostate-specific antigen density may help reduce unnecessary biopsies while limiting missed clinically significant prostate cancer. A recent RadioGraphics review identifies PI-RADS 3 lesions as a persistent diagnostic grey zone and outlines ways to reduce uncertainty in scoring and management. The approach centres on consistent use of PI-RADS v2.1 rules, better image quality, greater reader expertise and additional risk markers rather than treating a PI-RADS 3 score as an automatic indication for biopsy. Emerging artificial intelligence and prostate-specific membrane antigen imaging may offer further support but still require validation.
PI-RADS 3 Remains a Diagnostic Grey Zone
PI-RADS 3 represents an intermediate or equivocal likelihood of clinically significant prostate cancer, making it difficult to classify these lesions as clearly positive or negative MRI findings. A recent meta-analysis found clinically significant cancer in 17% of PI-RADS 3 lesions, although detection varies with factors including previous biopsy status. This uncertainty can lead to inconsistent biopsy decisions across institutions and can affect the diagnostic performance of prostate MRI. Excessive use of the category is therefore a concern rather than a neutral reporting choice.
Correct application of PI-RADS v2.1 upgrading rules is one way to narrow the grey zone. In the peripheral zone, diffusion-weighted imaging is dominant and a category 3 lesion showing discrete early focal enhancement on dynamic contrast-enhanced imaging is upgraded to PI-RADS 4. In the transition zone, T2-weighted imaging is dominant and diffusion-weighted findings can trigger upgrading. Evidence on the cancer yield of upgraded lesions has varied between studies, but community-practice data and a meta-analysis of transition-zone lesions support adherence to the current upgrading rules.
The practical aim is to prevent lesions from remaining in category 3 simply because the imaging features are uncertain or the scoring rules are not applied consistently. PI-RADS 3 should remain an equivocal category defined by specific imaging criteria rather than a default label for findings that do not fit elsewhere.
Must Read: MRI-Based AI Shows Promise in Prostate Cancer Recurrence
Image Quality and Reader Experience Shape Scoring
Suboptimal image quality is associated with more PI-RADS 3 assessments and can make lesion characterisation less reliable. Motion, rectal air and poor signal quality may reduce lesion conspicuity or obscure features needed for confident categorisation. The Prostate Imaging Quality system, PI-QUAL, provides a structured approach to classifying examination quality, while adherence to PI-RADS-compliant acquisition and patient preparation strategies can reduce artefacts. Postprocedural changes can also complicate interpretation, particularly haemorrhage after biopsy, which may mimic suspicious MRI features.
Reader experience is another important source of variation. Less experienced radiologists tend to assign PI-RADS 3 more frequently and this category has shown particularly low interobserver agreement. Some PI-RADS v2.1 descriptors still require subjective assessment, leaving room for uncertainty even though reliability has improved compared with the previous version. Training, expert review and more objective scoring criteria may therefore help reduce unnecessary equivocal classifications. Institutions may also monitor PI-RADS 3 rates among readers as a quality-control measure to assess guideline adherence and identify areas for improvement.
Contrast use adds another layer to the decision. Noncontrast prostate MRI has shown comparable diagnostic performance to contrast-enhanced MRI in systematic reviews, but dynamic contrast enhancement may increase confidence in selected cases and is part of the peripheral-zone upgrading pathway. Prospective comparisons are still needed that include lower-quality examinations and less experienced readers to better reflect routine practice.
Risk-Based Pathways Could Reduce Unnecessary Biopsy
A PI-RADS 3 score alone does not provide a clear indication for biopsy. MRI-focused pathways often recommend biopsy from PI-RADS 3 upwards, while more conservative thresholds can reduce biopsies but risk missing clinically significant disease. Risk-based pathways instead combine MRI findings with additional markers, particularly prostate-specific antigen density, to separate lower-risk patients from those more likely to benefit from biopsy. A commonly used PSA density threshold is 0.15 ng/mL/cm³, although thresholds vary between guidelines and institutions.
Evidence suggests this approach can preserve clinically significant cancer detection while increasing biopsy avoidance. In one large retrospective study of biopsy-naïve patients, a lower PSA density threshold for PI-RADS 3 lesions avoided 54.4% of biopsies while missing 1.6% of clinically significant cancers. The balance shifted with a higher threshold, reinforcing that risk cut-offs influence both biopsy avoidance and missed disease. Other ancillary markers may also complement MRI, although their incremental clinical benefit still requires comparison.
Artificial intelligence-based computer-aided diagnosis and prostate-specific membrane antigen PET imaging are also being explored to refine PI-RADS 3 assessment. Some studies report improved specificity, accuracy or risk stratification, but results are not uniformly superior to multidisciplinary radiology practice. These tools remain constrained by image quality, scanner variability, training data and limited evidence on incremental value or cost-effectiveness, so broader adoption requires further prospective validation.
PI-RADS 3 lesions remain one of the most difficult areas of prostate MRI because an equivocal score can lead either to unnecessary biopsy or delayed detection of clinically significant cancer. More consistent use of PI-RADS upgrading rules, stronger image-quality controls and better reader training can reduce avoidable uncertainty at the interpretation stage. For management, combining MRI with prostate-specific antigen density offers a practical risk-based route to more selective biopsy decisions. Artificial intelligence and prostate-specific membrane antigen imaging may further refine this process, but current evidence does not yet support routine replacement of established diagnostic pathways.
Source: RadioGraphics
Image Credit: iStock
References:
Nicola R, de Oliveira Correia ET, de Moraes Antunes P et al. (2026) Navigating PI-RADS 3 Lesions: Reducing Uncertainty and Guiding Prostate Cancer Diagnostic Decision Making. RadioGraphics; 46:9.
